This review highlights that reprogramming key immune subsets—such as exhausted CD8+ T cells, M2-like TAMs, and suppressive MDSCs—may represent a transformative approach in NSCLC treatment. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.